Project Name: Salford Dermatology HS and PsO service development
Project Summary:
The main objective of the Collaborative Working Project (“CWP”) is to improve the quality of care delivered to psoriasis (PsO) and hidradenitis suppurativa (HS) patients at the Trust in line with the National Institute for Clinical Excellence (NICE) and National British Association of Dermatology (BAD) guidelines. This CWP will improve the current hospital-based service at the Trust by deploying 2 Band 6 Dermatology Clinical Nurse Specialists (CNS), to the Dermatology department. The band 6 Dermatology CNS’s will be responsible for supporting the current nurse led new patient PsO service at the Trust, developing a specialist HS nurse led service and reviewing the severe HS patients including supporting with education counselling and providing with a dressing service. They will also be responsible for supporting the PsO and HS service and support the team to screen and initiate Biologic therapies,where appropriate according to NICE.
Planned Milestones:
- Kick off meeting
- Recruitment of Band 6 clinical nurse specialists (CNS), Collection of Baseline data Quarterly review meeting between Novartis and CWP. Creation of satisfaction survey.
- Carry out 3 months of clinical operations according to the developed protocols. Quarterly review meeting between Novartis and CWP.
- Carry out 6 months of clinical operations according to the developed protocols. Quarterly review meeting between Novartis and CWP
- Carry out 9 months of clinical operations according to the developed protocols. Quarterly review meeting between Novartis and CWP.
- Carry out 12 months of clinical operations according to the developed protocols. Quarterly review meeting between Novartis and CWP.
- Submission of business case
- Review meeting between Novartis and CWP.
- Analysis of CWP data, submission of Final Project Report, Submission of Outcomes Summary.
Expected Benefits:
For the Patient:
- Improved access to diagnosis,treatment and ongoing optimised management of PsO and HS.
- More equitable and consistent access to care,
- Enhanced experience for patients and their carers who live with PsO and HS.
- Access to a bespoke service for HS patients across Greater Manchester.
For the NHS:
- Increase the overall quality of care for PsO and HS patients in Greater Manchester,
- Improve equity of access to specialist care for patients with HS and PsO.
- Decrease patient waiting times,
- Decrease number of unnecessary out-patient appointments and hospital in-patient stays.
For Novartis:
- Insight on appropriate use of approved NICE medicines (including Novartis’ therapies) in appropriate patients,
- This project will support Novartis’ reputation and vision to make an impact in patients' lives by improving the quality of patient care within the NHS,
- Ethical, professional and transparent relationship and trust between Novartis and the NHS.
Start Date & Duration: February 2025 Duration 20 months
FA-11362114 | February 2025